PL3033086T3 - Terapia skojarzona do leczenia nowotworów złośliwych - Google Patents

Terapia skojarzona do leczenia nowotworów złośliwych

Info

Publication number
PL3033086T3
PL3033086T3 PL14752433T PL14752433T PL3033086T3 PL 3033086 T3 PL3033086 T3 PL 3033086T3 PL 14752433 T PL14752433 T PL 14752433T PL 14752433 T PL14752433 T PL 14752433T PL 3033086 T3 PL3033086 T3 PL 3033086T3
Authority
PL
Poland
Prior art keywords
cancer
treatment
combination therapy
therapy
combination
Prior art date
Application number
PL14752433T
Other languages
English (en)
Inventor
Yan Chen
Xizhong Huang
Sunkyu Kim
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51355593&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3033086(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL3033086T3 publication Critical patent/PL3033086T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
PL14752433T 2013-08-14 2014-08-07 Terapia skojarzona do leczenia nowotworów złośliwych PL3033086T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361865804P 2013-08-14 2013-08-14
US201361894029P 2013-10-22 2013-10-22
EP14752433.4A EP3033086B1 (en) 2013-08-14 2014-08-07 Combination therapy for the treatment of cancer
PCT/IB2014/063782 WO2015022609A1 (en) 2013-08-14 2014-08-07 Combination therapy for the treatment of cancer

Publications (1)

Publication Number Publication Date
PL3033086T3 true PL3033086T3 (pl) 2022-01-31

Family

ID=51355593

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14752433T PL3033086T3 (pl) 2013-08-14 2014-08-07 Terapia skojarzona do leczenia nowotworów złośliwych

Country Status (20)

Country Link
US (9) US20160184311A1 (pl)
EP (2) EP4005573A1 (pl)
JP (2) JP2016528246A (pl)
KR (4) KR102529049B1 (pl)
CN (2) CN105828822B (pl)
AU (3) AU2014307633A1 (pl)
BR (1) BR112016002465B1 (pl)
CA (1) CA2918190C (pl)
CY (1) CY1124810T1 (pl)
DK (1) DK3033086T3 (pl)
ES (1) ES2900829T3 (pl)
HR (1) HRP20211879T1 (pl)
HU (1) HUE057061T2 (pl)
LT (1) LT3033086T (pl)
MX (2) MX384403B (pl)
PL (1) PL3033086T3 (pl)
PT (1) PT3033086T (pl)
RU (1) RU2680714C2 (pl)
SI (1) SI3033086T1 (pl)
WO (1) WO2015022609A1 (pl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102529049B1 (ko) 2013-08-14 2023-05-08 노파르티스 아게 암의 치료를 위한 조합 요법
MX376083B (es) 2015-06-04 2025-03-07 Pfizer Formas de dosificacion solidas de palbociclib.
CN105130992B (zh) * 2015-07-16 2018-02-09 苏州大学 具有激酶抑制活性的含氮杂环化合物、制备方法和用途
WO2017021177A1 (en) * 2015-08-04 2017-02-09 Universitat De Barcelona Pharmaceutical combinations for use in the treatment of cancer
US10328066B2 (en) 2015-08-28 2019-06-25 Novartis Ag Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the CDK4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer
CN107921037A (zh) * 2015-08-28 2018-04-17 诺华股份有限公司 含pi3k抑制剂alpelisib和b‑raf抑制剂达拉菲尼的药物组合；该组合在治疗或预防癌症中的应用
CN108697807B (zh) * 2016-01-11 2021-11-26 辛德弗雷克斯公司 代谢功能障碍引起的肿瘤的治疗
CN107137409A (zh) * 2016-03-01 2017-09-08 江苏恒瑞医药股份有限公司 一种cdk4/6抑制剂与雌激素受体拮抗剂联合在制备治疗乳腺癌的药物中的用途
CN107137408A (zh) * 2016-03-01 2017-09-08 江苏恒瑞医药股份有限公司 一种cdk4/6抑制剂与芳香化酶抑制剂联合在制备治疗乳腺癌的药物中的用途
KR20180119570A (ko) * 2016-03-15 2018-11-02 메리맥 파마슈티컬즈, 인크. 항-ErbB3 항체를 포함하는 병용 요법을 이용한 ER+, HER2-, HRG+ 유방암의 치료
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
WO2018001270A1 (en) * 2016-06-30 2018-01-04 Noratech Pharmaceuticals, Inc. Palbociclib prodrugs and composition thereof
WO2018017410A1 (en) 2016-07-22 2018-01-25 Eli Lilly And Company Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of breast cancer
CN109803684B (zh) * 2016-08-23 2022-08-23 卫材 R&D 管理有限公司 用于治疗肝细胞癌的组合疗法
US11083722B2 (en) 2017-03-16 2021-08-10 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of breast cancer
EP3434272A1 (en) * 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
MX2020001253A (es) * 2017-08-03 2020-07-13 Novartis Ag Combinacion terapeutica de un inhibidor tirosina quinasa del egfr de tercera generacion y un inhibidor de quinasa dependiente de ciclina.
CN111315378A (zh) 2017-11-16 2020-06-19 诺华股份有限公司 包含lsz102和瑞博西尼的药物组合
WO2019106604A1 (en) 2017-12-01 2019-06-06 Novartis Ag Pharmaceutical combination comprising lsz102 and alpelisib
JP7413363B2 (ja) 2018-09-07 2024-01-15 サノフイ メチル６－（２，４－ジクロロフェニル）－５－［４－［（３ｓ）－１－（３－フルオロプロピル）ピロリジン－３－イル］オキシフェニル］－８，９－ジヒドロ－７ｈ－ベンゾ［７］アヌレン－２－カルボキシレートの調製方法
CN113453721B (zh) 2018-10-26 2025-09-16 辛德弗雷克斯公司 Metap2抑制剂的生物标志物及其应用
WO2021063967A1 (en) 2019-10-01 2021-04-08 Sanofi Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof
WO2021110122A1 (zh) * 2019-12-05 2021-06-10 基石药业（苏州）有限公司 Cdk4/6抑制剂的组合疗法
KR20220113695A (ko) 2019-12-09 2022-08-16 사노피 7h-벤조[7]아눌렌-2-카르복실산 유도체의 결정질 형태
TW202146007A (zh) 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
TWI800827B (zh) * 2020-05-12 2023-05-01 美商建南德克公司 使用包含gdc-9545及cdk4/6抑制劑之組合療法治療乳癌
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
WO2022084280A1 (en) 2020-10-19 2022-04-28 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
WO2022184146A1 (zh) * 2021-03-03 2022-09-09 正大天晴药业集团股份有限公司 Cdk4/6抑制剂的联用药物组合物及其用途
CN117222411B (zh) * 2021-03-24 2026-03-27 贝达药业股份有限公司 药物组合、包含其的试剂盒及其用途
TW202304424A (zh) * 2021-04-12 2023-02-01 法商賽諾菲公司 包含依維莫司和安森司群的組合
TW202304425A (zh) * 2021-04-12 2023-02-01 法商賽諾菲公司 包含瑞博西尼和安森司群（ａｍｃｅｎｅｓｔｒａｎｔ）的組合
CA3232226A1 (en) * 2021-09-27 2023-03-30 Fan FENG Combined pharmaceutical composition of cdk4/6 inhibitor and aromatase inhibitor
KR102658209B1 (ko) * 2021-10-05 2024-04-18 재단법인 아산사회복지재단 Cdk 억제제 및 id2 활성화제를 포함하는 방광암의 예방 또는 치료용 약학 조성물
JP2024540529A (ja) * 2021-11-18 2024-10-31 オンコノヴァ セラピューティクス， インコーポレイテッド がんを処置するための方法および組成物
IL312650A (en) * 2021-12-02 2024-07-01 Pfizer CDK4 inhibitor for cancer treatment
WO2024107955A1 (en) * 2022-11-17 2024-05-23 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
EP4626890A1 (en) 2022-12-01 2025-10-08 KRKA, d.d., Novo mesto Ribociclib salts and formulations thereof
KR20250163966A (ko) 2023-03-27 2025-11-21 노파르티스 아게 리보시클립과 아로마타제 저해제를 병용하여 초기 유방암을 치료하는 방법
TW202602868A (zh) 2024-04-15 2026-01-16 瑞士商諾華公司 瑞波西利的藥物組成物

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749713A (en) 1986-03-07 1988-06-07 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
US4978672A (en) 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
JP2710053B2 (ja) 1988-07-05 1998-02-10 スズキ株式会社 自動車の車体構造
GB9414045D0 (en) 1994-07-12 1994-08-31 Berwind Pharma Service Moisture barrier film coating composition, method, and coated form
CA2297967A1 (en) 1997-08-07 1999-02-18 The Regents Of The University Of California Purine inhibitor of protein kinases, g proteins and polymerases
ITMI992711A1 (it) 1999-12-27 2001-06-27 Novartis Ag Composti organici
ATE322494T1 (de) 2000-01-07 2006-04-15 Universitaire Instelling Antwe Purin derivate, ihre herstellung und verwendung
EP1485390B1 (en) 2002-03-07 2008-10-08 F. Hoffman-la Roche AG Bicyclic pyridine and pyrimidine p38 kinase inhibitors
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
US20060106227A1 (en) 2002-06-13 2006-05-18 Dr Reddy's Laboratories Limited 3-'2-(Dimethylamino) ethyl!-n-methyl-1h-indole-5-methanesulfonamide and the succinate thereof
WO2004022561A1 (en) 2002-09-04 2004-03-18 Schering Corporation Pyrazolopyrimidines as cyclin-dependent kinase inhibitors
US7196092B2 (en) * 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7605155B2 (en) * 2002-09-04 2009-10-20 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
EP1590341B1 (en) 2003-01-17 2009-06-17 Warner-Lambert Company LLC 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
US7194572B2 (en) 2003-08-08 2007-03-20 Intel Corporation Memory system and method to reduce reflection and signal degradation
US20050113379A1 (en) 2003-09-05 2005-05-26 Ping Ge Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands
US7749999B2 (en) 2003-09-11 2010-07-06 Itherx Pharmaceuticals, Inc. Alpha-ketoamides and derivatives thereof
US7319102B1 (en) 2003-12-09 2008-01-15 The Procter & Gamble Company Pyrrolo[2,3-d]pyrimidine cytokine inhibitors
EP1713806B1 (en) 2004-02-14 2013-05-08 Irm Llc Compounds and compositions as protein kinase inhibitors
JP2007526906A (ja) 2004-03-05 2007-09-20 大正製薬株式会社 ピロロピリミジン誘導体
WO2005107760A1 (en) 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation
WO2006008545A2 (en) 2004-07-22 2006-01-26 Astex Therapeutics Limited Thiazole and isothiazole derivatives as protein kinase inhibitors
US7906528B2 (en) 2004-10-05 2011-03-15 Novartis International Pharmaceutical Ltd. Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
AU2005298637B8 (en) 2004-10-29 2012-12-06 Janssen Sciences Ireland Uc HIV inhibiting bicyclic pyrimidine derivatives
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7723340B2 (en) 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
EP1846408B1 (en) 2005-01-14 2013-03-20 Janssen Pharmaceutica NV 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
US8279985B2 (en) 2005-02-22 2012-10-02 Adaptix, Inc. Intelligent demodulation systems and methods in an OFDMA multicell network
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
JP2006241089A (ja) 2005-03-04 2006-09-14 Astellas Pharma Inc ピロロピリミジン誘導体またはその塩
WO2007030438A2 (en) 2005-09-06 2007-03-15 Pharmacopeia, Inc. Aminopurine derivatives for treating neurodegenerative diseases
GB0520164D0 (en) 2005-10-04 2005-11-09 Novartis Ag Organic compounds
JP2009514870A (ja) 2005-11-04 2009-04-09 ワイス ｍＴＯＲインヒビター、ハーセプチン、および／またはＨＫＩ−２７２の抗悪性腫瘍性組み合わせ
CA2628659A1 (en) 2005-11-11 2007-05-24 Pfizer, Inc. Combinations and methods of using an immunomodulatory oligodeoxynucleotide
WO2007058990A2 (en) 2005-11-14 2007-05-24 Kemia, Inc. Therapy using cytokine inhibitors
WO2007075783A2 (en) 2005-12-22 2007-07-05 Wyeth Substituted isoquinoline-1,3(2h,4h)-diones, 1-thioxo-1,4-dihydro-2h-isoquinoline-3-ones and 1,4-dihydro-3(2h)-isoquinolones and use thereof as kinase inhibitor
GB0526246D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
CA2646429A1 (en) 2006-03-09 2007-09-13 Pharmacopeia, Inc. 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders
WO2007104222A1 (fr) 2006-03-14 2007-09-20 Yaoming Zhang Générateur photovoltaïque en forme de papillon, à condensation de lumière réfléchie
CA2651072A1 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
TWI398252B (zh) 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
WO2008009927A1 (en) 2006-07-18 2008-01-24 Astrazeneca Ab Use of fulvestrant and an aromatase inhibitor for treating breast cancer
US9259399B2 (en) 2007-11-07 2016-02-16 Cornell University Targeting CDK4 and CDK6 in cancer therapy
CA2708149A1 (en) 2007-12-13 2009-06-18 Novartis Ag Combinations of therapeutic agents for treating cancer
BRPI0821209A2 (pt) 2007-12-19 2019-09-24 Amgen Inc composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor.
UY31631A1 (es) 2008-02-06 2009-09-30 Nuevos derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino, sales de los mismos, procesos para su preparacion, composiciones farmacéuticas que los comprenden y aplicaciones
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
GB0819105D0 (en) 2008-10-17 2008-11-26 Chroma Therapeutics Ltd Pyrrolo-pyrimidine compounds
CA2754917A1 (en) * 2009-03-11 2010-09-16 Research Development Foundation Low molecular weight cyclin e (lmw-e) as a biomarker for personalization of cancer therapies
EP3406260B1 (en) 2009-05-13 2020-09-23 The University of North Carolina at Chapel Hill Cyclin dependent kinase inhibitors and methods of use
WO2011010349A1 (ja) 2009-07-23 2011-01-27 株式会社アドバンテスト 試験装置
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
UY33226A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
WO2011130232A1 (en) * 2010-04-13 2011-10-20 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR083797A1 (es) 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
UY34072A (es) * 2011-05-17 2013-01-03 Novartis Ag Derivados sustituidos de indol
CN103635189B (zh) * 2011-07-01 2016-05-04 诺华股份有限公司 用于治疗癌症的含有cdk4/6抑制剂和pi3k抑制剂的联合治疗
US20210228529A1 (en) * 2012-07-13 2021-07-29 University Of Tennessee Research Foundation Pharmaceutical compositions for treating breast cancers and methods of uses thereof
EP2742940B1 (en) 2012-12-13 2017-07-26 IP Gesellschaft für Management mbH Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily
US9867825B2 (en) 2012-12-20 2018-01-16 Novartis Ag Pharmaceutical combination comprising binimetinib
WO2014203129A1 (en) * 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
KR102529049B1 (ko) 2013-08-14 2023-05-08 노파르티스 아게 암의 치료를 위한 조합 요법
WO2015069266A1 (en) 2013-11-07 2015-05-14 Flynn Daniel L Methods for inhibiting tie2 kinase useful in the treatment of cancer
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
HUE061213T2 (hu) 2015-04-16 2023-05-28 Novartis Ag Ribociklib tabletta
CN111315378A (zh) * 2017-11-16 2020-06-19 诺华股份有限公司 包含lsz102和瑞博西尼的药物组合

Also Published As

Publication number Publication date
CY1124810T1 (el) 2022-11-25
US20250170134A1 (en) 2025-05-29
EP4005573A1 (en) 2022-06-01
US20190046533A1 (en) 2019-02-14
WO2015022609A1 (en) 2015-02-19
US20240066034A1 (en) 2024-02-29
CN110368497A (zh) 2019-10-25
HUE057061T2 (hu) 2022-04-28
EP3033086B1 (en) 2021-09-22
LT3033086T (lt) 2021-12-27
MX2016001793A (es) 2016-05-18
AU2019202674B2 (en) 2020-07-23
CN105828822A (zh) 2016-08-03
DK3033086T3 (da) 2022-01-03
US20230405011A1 (en) 2023-12-21
ES2900829T3 (es) 2022-03-18
PT3033086T (pt) 2021-12-15
CA2918190C (en) 2023-01-17
MX2020002150A (es) 2021-07-07
AU2019202674A1 (en) 2019-05-16
US20220193079A1 (en) 2022-06-23
AU2017213541B2 (en) 2019-01-24
KR20160041920A (ko) 2016-04-18
US20160184311A1 (en) 2016-06-30
AU2017213541A1 (en) 2017-08-31
MX378263B (es) 2025-03-10
HRP20211879T1 (hr) 2022-03-04
KR20240160682A (ko) 2024-11-11
KR102318306B1 (ko) 2021-10-28
RU2016108667A3 (pl) 2018-07-10
RU2016108667A (ru) 2017-09-14
CA2918190A1 (en) 2015-02-19
KR102736746B1 (ko) 2024-12-03
SI3033086T1 (sl) 2022-01-31
CN110368497B (zh) 2022-05-13
RU2680714C2 (ru) 2019-02-26
US12544380B2 (en) 2026-02-10
AU2014307633A1 (en) 2016-02-11
BR112016002465B1 (pt) 2022-09-20
BR112016002465A2 (pt) 2017-08-01
US20240016808A1 (en) 2024-01-18
JP2016528246A (ja) 2016-09-15
KR20230067702A (ko) 2023-05-16
KR20210132219A (ko) 2021-11-03
US12544379B2 (en) 2026-02-10
US20250177402A1 (en) 2025-06-05
JP2019131570A (ja) 2019-08-08
CN105828822B (zh) 2019-10-18
MX384403B (es) 2025-03-14
EP3033086A1 (en) 2016-06-22
US20230398121A1 (en) 2023-12-14
RU2019104078A (ru) 2019-04-08
KR102529049B1 (ko) 2023-05-08

Similar Documents

Publication Publication Date Title
PL3033086T3 (pl) Terapia skojarzona do leczenia nowotworów złośliwych
IL245731A0 (en) Combined treatment for cancer
IL244014A0 (en) Combined therapy for the treatment of glioblastoma
LT2804599T (lt) Kombinuota terapija vėžio gydymui
GB201322725D0 (en) Cancer therapy
IL263781A (en) Combined treatment of ovarian cancer
SG10201913730RA (en) Cancer therapy
PL3089749T3 (pl) Preparaty skojarzone do leczenia raka
SG11201507847UA (en) Cancer therapy
PL3062790T3 (pl) Połączenia farmaceutyczne do leczenia raka
IL242546A0 (en) New compounds for cancer treatment
IL258494A (en) Rational combined therapy for cancer treatment
EP2961412A4 (en) CANCER THERAPY
GB201403083D0 (en) Treatment of cancer
PL3016948T3 (pl) 2-acyloaminotiazole do leczenia nowotworów
GB201317564D0 (en) Therapeutic for the treatment of Lung Cancer
IL233495A0 (en) Combination for cancer treatment
GB201322346D0 (en) Combination treatment of cancer
GB201322347D0 (en) Treatment of cancer
GB201318742D0 (en) Treatment of cancer
GB201308529D0 (en) Treatment of cancer
GB201305020D0 (en) Treatment of cancer
AP2015008905A0 (en) Novel compounds for the treatment of cancer
GB201317213D0 (en) Cancer Therapy